Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
The emergence of novel and evolving variants of SARS-CoV-2 has fostered the need for
change in the form of newer and more adaptive diagnostic methods for the detection of …
change in the form of newer and more adaptive diagnostic methods for the detection of …
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
[HTML][HTML] Efficacy and safety of an Ad26. RSV. preF–RSV preF protein vaccine in older adults
AR Falsey, K Williams, E Gymnopoulou… - … England Journal of …, 2023 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) can cause serious lower respiratory tract
disease in older adults, but no licensed RSV vaccine currently exists. An adenovirus …
disease in older adults, but no licensed RSV vaccine currently exists. An adenovirus …
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
D Goldblatt, G Alter, S Crotty… - Immunological reviews, 2022 - Wiley Online Library
Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …
Emerging concepts in the science of vaccine adjuvants
B Pulendran, P S. Arunachalam… - Nature Reviews Drug …, 2021 - nature.com
Adjuvants are vaccine components that enhance the magnitude, breadth and durability of
the immune response. Following its introduction in the 1920s, alum remained the only …
the immune response. Following its introduction in the 1920s, alum remained the only …
[HTML][HTML] T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
The use of viral vectors in vaccine development
T Travieso, J Li, S Mahesh, JDFRE Mello, M Blasi - npj Vaccines, 2022 - nature.com
Vaccines represent the single most cost-efficient and equitable way to combat and eradicate
infectious diseases. While traditional licensed vaccines consist of either …
infectious diseases. While traditional licensed vaccines consist of either …
COVID-19 vaccines: The status and perspectives in delivery points of view
Due to the high prevalence and long incubation periods often without symptoms, the severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals …
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic …
CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic …
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
More than 190 vaccines are currently in development to prevent infection by the novel
severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while …
severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while …